DNA strand with methylation marks over bone marrow cells.

ITGBL1 Methylation: A New Key to Understanding AML Prognosis?

Rhea Morgan in Health & Wellness October 2026 • 5 min read.

"Research uncovers how ITGBL1 methylation impacts acute myeloid leukemia, offering potential for improved risk assessment and treatment monitoring."

Acute myeloid leukemia (AML) is a type of cancer affecting the blood and bone marrow, characterized by the rapid growth of abnormal white blood cells. While treatments have improved, predicting how the disease will progress in individual patients remains a challenge. Doctors rely on various factors, including genetic mutations and cytogenetic abnormalities, to assess risk and tailor therapy.

In the relentless quest to understand and combat AML, researchers are constantly exploring new molecular markers that could offer insights into disease behavior. One such area of interest is DNA methylation, a process that can alter gene expression without changing the underlying DNA sequence. Aberrant DNA methylation patterns have been linked to various cancers, including AML, making them a potential target for diagnostic and therapeutic interventions.

A recent study has focused on the role of ITGBL1 (integrin beta-like 1) methylation in AML. ITGBL1 is a gene involved in cell adhesion and interactions with the extracellular matrix. The study, published in the Journal of Cellular Physiology, investigates how methylation of the ITGBL1 gene affects the prognosis of AML patients, potentially opening new avenues for risk stratification and treatment monitoring.

AI Search Multiple angles on this topic

Stats & Impact

Methylation and AML Prognosis

Aberrant DNA methylation is described as a hallmark of AML and may help stratify patients and identify biomarkers for treatment decisions and outcome prediction pmc.ncbi.nlm.nih.gov. A 2018 study reported significantly higher ITGBL1 methylation in patients with AML than in controls, and shorter overall survival among ITGBL1-hypermethylated patients onlinelibrary.wiley.com. The scale of these findings is not specified in the supplied excerpts. A 2025 study developed DNA methylation-based models to predict five-year outcomes, while noting that methylation’s prognostic and diagnostic roles in AML remain to be explored nature.com.

Standard Approach

Methylation Pathway Mutations

A 2025 abstract describes DNA methylation in CpG islands as important to epigenetic regulation and frequently altered in acute myeloid leukemia. It reports that somatic mutations in genes involved in the DNA methylation pathway are common in AML and may affect treatment response and patient survival. The supplied excerpt does not identify specific accepted prognostic methods or detail their limitations.

History

CN-AML Methylation Biomarkers

A 2024 study explored DNA methylation markers for stratifying patients with cytogenetically normal AML (CN-AML), a group typically categorized as intermediate-risk. It identified nine 5′-cytosine-phosphate-guanine-3′ sites as potential prognostic biomarkers. These sites distinguished patients with an adverse intermediate-poor prognosis from those with a more favorable intermediate-favorable prognosis.

What is ITGBL1 Methylation and Why Does It Matter in AML?

DNA strand with methylation marks over bone marrow cells.

Methylation is a chemical modification that occurs when a methyl group (CH3) is added to a DNA molecule. This process can affect gene expression, typically leading to gene silencing. In cancer, abnormal methylation patterns can disrupt the normal function of genes involved in cell growth, differentiation, and apoptosis. ITGBL1, or integrin beta-like 1, is a gene that encodes a protein related to integrins, which are involved in cell adhesion and interactions with the surrounding environment. The ITGBL1 protein contains multiple epidermal growth factor (EGF)-like domains and plays a role in cell-matrix interactions.

The study aimed to investigate the methylation pattern of the ITGBL1 gene in patients with AML and its clinical relevance. Researchers analyzed bone marrow samples from 131 newly diagnosed AML patients and 29 healthy controls. They used real-time methylation-specific polymerase chain reaction (RQ-MSP) and bisulfite sequencing PCR (BSP) to detect methylation in the ITGBL1 promoter region. Additionally, they performed real-time quantitative PCR (RT-qPCR) to measure ITGBL1 transcript levels.

Higher Methylation in AML Patients: The study found that ITGBL1 methylation levels were significantly higher in AML patients compared to healthy controls, indicating that ITGBL1 is frequently hypermethylated in AML.
Correlation with Clinical Outcomes: ITGBL1-hypermethylated patients tended to have higher bone marrow blast counts and lower complete remission rates, suggesting a link between ITGBL1 methylation and disease severity.
Impact on Survival: ITGBL1-hypermethylated patients had significantly shorter overall survival (OS) and leukemia-free survival (LFS) compared to those with lower ITGBL1 methylation levels. This finding suggests that ITGBL1 methylation is associated with a poorer prognosis in AML.

AI Search Multiple angles on this topic

Latest Research

Research Directions in AML

A September 2024 review updates standard-of-care and investigational therapies and outlines current and future research directions. The supplied excerpt also reports that a study using DNA methylation data from the 450K array identified 2,549 CpG sites in a training set that could potentially distinguish CN-AML patients with intermediate-poor outcomes from those with intermediate-favorable outcomes, independent of age. The excerpt characterizes AML as aggressive, heterogeneous, and affected by suboptimal risk stratification. It does not establish that these findings concern ITGBL1 specifically.

Counterpoints

Validation Remains a Barrier

A validation study of potential prognostic DNA methylation biomarkers in AML reports that these epigenetic markers have not been thoroughly validated. As a result, the study says they are still not considered in clinical practice. The supplied excerpt does not specify which markers failed validation or provide validation statistics.

Comparison

ITGBL1 Methylation in Patients and Controls

A study comparing AML patients with controls found significantly higher ITGBL1 methylation in 131 patients than in 29 controls (p < 0.001). This supports a difference between the groups in that study, but the supplied excerpt does not report survival outcomes or show that ITGBL1 methylation can distinguish individual patients’ prognoses.

The researchers also found that ITGBL1 methylation levels decreased in AML patients who achieved complete remission after induction therapy. Moreover, ITGBL1 methylation was negatively correlated with ITGBL1 expression, meaning that higher methylation levels were associated with lower ITGBL1 transcript levels. Demethylation of ITGBL1 could increase the ITGBL1 expression in the K562 leukemic cell line. These results indicate that ITGBL1 methylation can affect gene expression and disease progression in AML.

Future Directions and Clinical Implications

This research suggests that ITGBL1 hypermethylation is a potential biomarker for predicting prognosis and monitoring disease status in patients with AML. Further studies are needed to validate these findings in larger patient cohorts and to investigate the underlying mechanisms by which ITGBL1 methylation affects AML progression. Understanding these mechanisms could lead to the development of targeted therapies to reverse ITGBL1 methylation and improve outcomes for AML patients. Future research could also explore the potential of using ITGBL1 methylation status to stratify patients for different treatment approaches, personalizing therapy based on individual risk profiles.

How the reported measurements compare

R = -0.328; p = 0.008The reported correlation between ITGBL1 methylation and expression was negative (R = -0.328; p = 0.008), indicating that higher methylation tended to occur alongside lower expression in the measured patients.^[1]

How the findings fit broader AML methylation research

The broader AML literature describes methylation patterns as possible markers for early tumor detection, risk stratification, treatment response, and prognosis. That framing concerns methylation generally, rather than validating ITGBL1 for any of those uses.^[2]

A separate validation effort argues that independent validation is needed before prognostic methylation changes can be established for clinical use. This is a general barrier for epigenetic markers, not a direct assessment of ITGBL1.^[3]

What further evidence would clarify ITGBL1 methylation

Would independent patient cohorts reproduce the relationship between ITGBL1 methylation and survival, given the broader concern that methylation markers need independent validation?^{[1] [3]}
Does the cell-line observation that demethylation accompanies increased ITGBL1 expression also hold in patient disease, or is it limited to that laboratory setting?^[1]

Sources

Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia. (pubmed.ncbi.nlm.nih.gov)
DNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome (pmc.ncbi.nlm.nih.gov)
A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What exactly is ITGBL1 methylation, and how does it relate to acute myeloid leukemia (AML)?

ITGBL1 methylation refers to the addition of a methyl group to the ITGBL1 gene, which is involved in cell adhesion and interactions with the extracellular matrix. In AML, increased methylation of ITGBL1 is associated with reduced gene expression. This abnormal methylation pattern can disrupt normal cellular processes, potentially contributing to disease progression. The study found that higher ITGBL1 methylation levels correlated with poorer clinical outcomes, such as shorter overall survival and leukemia-free survival, indicating its relevance in AML prognosis.

2

How was ITGBL1 methylation measured in the AML study, and what were the key findings regarding its levels in AML patients versus healthy individuals?

In the AML study, ITGBL1 methylation was detected using real-time methylation-specific polymerase chain reaction (RQ-MSP) and bisulfite sequencing PCR (BSP) on bone marrow samples. The key finding was that ITGBL1 methylation levels were significantly higher in AML patients compared to healthy controls. This indicates that ITGBL1 is frequently hypermethylated in AML, suggesting its potential as a biomarker for the disease. Further analysis showed a negative correlation between ITGBL1 methylation and ITGBL1 expression, meaning higher methylation levels were associated with lower ITGBL1 transcript levels.

3

What clinical outcomes are associated with ITGBL1 hypermethylation in AML patients, and why is this significant for predicting disease progression?

ITGBL1 hypermethylation in AML patients is associated with several adverse clinical outcomes. Patients with higher ITGBL1 methylation levels tend to have higher bone marrow blast counts and lower complete remission rates. More critically, these patients also exhibit significantly shorter overall survival (OS) and leukemia-free survival (LFS). These findings suggest that ITGBL1 methylation is a strong indicator of disease severity and poorer prognosis in AML, making it significant for predicting disease progression and potentially guiding treatment decisions. Further research is needed to fully understand how ITGBL1 methylation affects AML progression, which may lead to targeted therapies that reverse ITGBL1 methylation.

4

Besides prognosis, what other clinical implications does ITGBL1 methylation have for managing AML, and what future research directions are planned?

Beyond predicting prognosis, ITGBL1 methylation has potential implications for monitoring disease status in AML patients. The study showed that ITGBL1 methylation levels decreased in patients who achieved complete remission after induction therapy, suggesting it could be used to track treatment response. Future research aims to validate these findings in larger patient groups and explore the mechanisms by which ITGBL1 methylation affects AML progression. This could lead to targeted therapies designed to reverse ITGBL1 methylation, improving outcomes for AML patients. Additionally, ITGBL1 methylation status could be used to stratify patients for different treatment approaches, personalizing therapy based on individual risk profiles.

5

How does ITGBL1 methylation affect ITGBL1 gene expression, and what are the implications of this relationship for AML?

ITGBL1 methylation negatively correlates with ITGBL1 expression; higher methylation levels are associated with lower ITGBL1 transcript levels. This means that when the ITGBL1 gene is more methylated, less of the ITGBL1 protein is produced. Since ITGBL1 is involved in cell adhesion and interactions with the extracellular matrix, reduced ITGBL1 expression can disrupt normal cellular functions, potentially contributing to AML progression. Restoring ITGBL1 expression through demethylation could be a potential therapeutic strategy. The study also found that demethylation of ITGBL1 could increase the ITGBL1 expression in the K562 leukemic cell line.